Connect with us

Hi, what are you looking for?

Over the Counter (OTC) Drugs & Dietary Supplements Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis and Forecast To 2023

The Allied Market Research published a report on Over the Counter (OTC) Drugs & Dietary Supplements Market 2017-2023, Interesting fact and figures (CAGR, Global Size, Shares and Revenue with Business Growth Support and Market Value and Volume with Supply Demand Scenario and Pipeline Projects). Global over the Counter (OTC) Drugs & Dietary Supplements Market was valued at $223 billion in 2016, and is expected to reach $335 billion by 2023, registering a CAGR of 5.9% from 2017 to 2023.

Over the counter (OTC) drugs are defined as non-prescription medicines which are sold without the prescription from a healthcare professional. Regulated by active pharmaceutical ingredients (APIs), they are easily available in pharmacies and online health websites. Dietary supplements offer essential nutrients required by the body as well as non-nutrient chemicals, which have biologically beneficial effects in the body.

Download Report Sample with Industry Insights @ https://www.alliedmarketresearch.com/request-sample/2695

The market for OTC drugs is witnessing a rapid growth in recent years, owing to change in lifestyle & aging of baby boomers, the rise in awareness of general health concerns, and increased tendency among individuals to choose OTC drugs. However, stringent regulations by governing organizations like the FDA, resulted in the delayed approval of drugs, which act as an impediment for the market growth. On the other hand, increase in R&D activities by the market players to improve OTC drugs for the treatment of conditions such as laxatives, oral antiseptics, analgesics, and anti-smoking products offer lucrative opportunities for the market players.

Among the categories discussed in the report, the cough & cold products segment is likely to grow at a CAGR of 6.1% during the forecast period, 2017 – 2023. As cough and cold is the most frequent ailment acquired by consumers globally, the sales of OTC drugs have increased. The gastrointestinal products segment is also an attractive segment owing to the growing sales of OTC drug for treating gastrointestinal disorders such as diarrhea, constipation, indigestion, vomiting, etc.

Among the dosage forms, the tablets segment was the largest market in 2016, accounting for nearly two-ninths of the market share. The same is likely to maintain this trend during the study period. This is because of increased occurrence of diseases globally along with the benefits of consuming tablets and provision of accurate dosage level for various types of patient. Moreover, the soft capsules segment is likely to grow at the fastest CAGR of 6.6% through 2023.

Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2695

In 2016, Asia-Pacific and LAMEA together occupied nearly half of the market share and is likely to maintain their dominance through 2023. The is due to the growing awareness of OTC drugs, dietary supplements, and occurrence of common ailments such as cold & cough, infectious diseases, oral diseases, and other. Moreover, greater availability of such drugs, especially in China, India, and the other developing nations to meet the growing demand is expected to drive the market.

The report offers an analysis of the leading companies providing solutions in the field and they include Pfizer Inc., Novartis International AG., Roche Holding AG, Merck & Co., Inc., Sanofi S.A, Johnson & Johnson, Gilead Sciences, GlaxoSmithKline plc., Bayer Healthcare AG, and AstraZeneca plc.

Key Findings Of The Over the Counter (OTC) Drugs & Dietary Supplements Market:

  • The U.S. was the major shareholder in the North America over the counter (OTC) drugs & dietary supplements market in 2016.
  • The branded OTC drugs segment occupied about three-fifths share of the global market by product in 2016, and is expected to retain its dominant position throughout the forecast period.
  • Japan occupied about one-third share of the Asia-Pacific market in 2016, whereas China is expected to grow rapidly registering a CAGR of 6.6%.
  • The pharmacies segment accounted for about half of the global market share in 2016, whereas the online pharmacy segment is expected to witness a high CAGR of 6.9%.

For More Information: https://www.alliedmarketresearch.com/over-the-counter-OTC-drugs-and-dietary-supplements-market

 About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

Toll Free: +1-800-792-5285

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

Web: www.alliedmarketresearch.com

Written By

You may also like:

Business

Catherine Berthet (L) and Naoise Ryan (R) join relatives of people killed in the Ethiopian Airlines Flight 302 Boeing 737 MAX crash at a...

Tech & Science

The groundbreaking initiative aims to provide job training and confidence to people with autism.

Tech & Science

Microsoft and Google drubbed quarterly earnings expectations.

Business

There is no statutory immunity. There never was any immunity. Move on.